Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 - ATLAS ACS 2-TIMI 51

Description:

Rivaroxaban is a novel oral anti-Xa antagonist, with demonstrated safety and efficacy, as compared with agents such as warfarin, in patients with atrial fibrillation and thromboembolism. The phase II ATLAS ACS–TIMI 46 trial noted that in patients with recent acute coronary syndrome (ACS), rivaroxaban, on a background of dual antiplatelet therapy with aspirin and clopidogrel, was associated with reasonable efficacy but increased bleeding as compared with placebo. Doses of 2.5 and 5 mg appe...